ACE2 and COVID-19: Two studies including a small case series of patients with long COVID identified methylation changes at one year after the initial SARS-CoV-2 infection [20,21], whereas our research group identified that the methylation levels of the ACE2 promoter were not related to the presence of long COVID symptoms in a cohort of previously hospitalized COVID-19 survivors [22].